胸腺肽辅助治疗慢性湿疹的临床观察

发布时间：2018-12-30 21:43

【摘要】：目的:观察胸腺肽辅助治疗慢性湿疹的临床疗效及安全性,从外周血T淋巴细胞亚群变化探讨该药的治疗机制。方法:将160例慢性湿疹患者按随机数字表法分成观察组和对照组,各80例。两组患者均给予咪唑斯汀、地奈德乳膏等常规治疗;观察组患者加用胸腺肽肠溶片20 mg,po,tid;对照组患者给予与胸腺肽肠溶片外观一致的安慰剂治疗。两组患者疗程均为4周。比较两组患者T淋巴细胞亚群的变化、临床疗效和不良反应发生情况,以及随访1年的复发率。结果:观察组患者的有效率(91.25%)显著高于对照组(77.50%),差异有统计学意义(P0.05);治疗后,两组患者的CD4~+和CD4~+/CD8~+均较治疗前显著升高,CD8+较治疗前显著降低,且观察组患者的CD4~+和CD4~+/CD8~+均显著高于对照组,差异均有统计学意义(P0.05),但组间CD8+比较差异无统计学意义(P0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P0.05),但随访期间观察组患者的复发率(31.51%)显著低于对照组(64.52%),差异有统计学意义(P0.05)。结论:胸腺肽可通过改善T淋巴细胞亚群来提高慢性湿疹患者的临床疗效、降低复发率,且用药安全。
[Abstract]:Aim: to observe the clinical efficacy and safety of thymosin in the treatment of chronic eczema and to explore the therapeutic mechanism of thymosin from the changes of T lymphocyte subsets in peripheral blood. Methods: 160 patients with chronic eczema were randomly divided into observation group and control group with 80 cases each. Both groups were treated with midazolastine and desonide cream, and the patients in the observation group were treated with placebo with thymosin enteric-coated tablets for 20 mg,po,tid;. The course of treatment was 4 weeks. The changes of T lymphocyte subsets, the clinical efficacy and adverse reactions, and the recurrence rate of 1 year follow-up were compared between the two groups. Results: the effective rate of the observation group (91.25%) was significantly higher than that of the control group (77.50%), the difference was statistically significant (P0.05). After treatment, the CD4~ and CD4~ / CD8~ of the two groups were significantly higher than those before the treatment, and the CD8 decreased significantly, and the CD4~ and CD4~ / CD8~ of the observation group were significantly higher than those of the control group (P0.05). However, there was no significant difference in CD8 between groups (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05), but the recurrence rate of the observation group (31.51%) was significantly lower than that of the control group (64.52%) during the follow-up period (P0.05). Conclusion: thymosin can improve the clinical efficacy of chronic eczema by improving T lymphocyte subsets and reduce the recurrence rate.
【作者单位】：台州恩泽医疗中心(集团)路桥医院皮肤性病科;台州市路桥区中医院内科;台州恩泽医疗中心(集团)路桥医院冷冻室;
【分类号】：R758.23

【相似文献】